dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Iacoboni García-Calvo, Gloria |
dc.contributor.author | Martinez-Cibrian, Nuria |
dc.contributor.author | Bailén, Rebeca |
dc.contributor.author | Corral, Lucia Lopez |
dc.contributor.author | Sanchez, Jose M. |
dc.contributor.author | Abrisqueta Costa, Pablo |
dc.contributor.author | Barba Suñol, Pere |
dc.contributor.author | Villacampa Javierre, Guillermo |
dc.date.accessioned | 2022-01-11T12:09:04Z |
dc.date.available | 2022-01-11T12:09:04Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Iacoboni G, Villacampa G, Martinez‐Cibrian N, Bailén R, Lopez Corral L, Sanchez JM, et al. Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma. Cancer Med. 2021 May;10(10):3214–3223. |
dc.identifier.issn | 2045-7634 |
dc.identifier.uri | https://hdl.handle.net/11351/6761 |
dc.description | Recerca clínica del càncer; Càncer hematològic; Limfoma no Hodgkin |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer Medicine;10(10) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Cèl·lules B - Tumors - Tractament |
dc.subject | Teràpia cel·lular |
dc.subject.mesh | Lymphoma, Large B-Cell, Diffuse |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Receptors, Antigen, T-Cell |
dc.subject.mesh | /therapeutic use |
dc.title | Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cam4.3881 |
dc.subject.decs | linfoma de células B grandes difuso |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | receptores de antígenos de linfocitos T |
dc.subject.decs | /uso terapéutico |
dc.relation.publishversion | https://doi.org/10.1002/cam4.3881 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Iacoboni G, Abrisqueta P, Barba P] Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Villacampa G] Oncology Data Science, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Martinez-Cibrian N] Department of Hematology, University Hospital Virgen del Rocio, Sevilla, Spain. [Bailén R] Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. [Lopez Corral L] Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain. [Sanchez JM] Hematology Department, Hospital 12 de Octubre, Madrid, Spain |
dc.identifier.pmid | 33932100 |
dc.identifier.wos | 000645922100001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/BDNS357800 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |